靶向膜结合阴离子磷脂的抗凝改善小鼠创伤性脑损伤结局
本研究在小鼠模型和体外实验中评估融合蛋白ANV-6L15对重型创伤性脑损伤(TBI)的治疗作用。ANV-6L15将磷脂酰丝氨酸结合蛋白annexin V与靶向外源性凝血的肽类抗凝剂结合,可减少颅内血肿、改善神经功能并降低死亡率,机制与抑制表达阴离子磷脂的细胞外囊泡促凝活性有关。
要点
- ANV-6L15使液压冲击伤小鼠颅内血肿减少70.2%、死亡减少56.8%。
- 脑源性细胞外囊泡(BDEVs)磷脂酰丝氨酸水平最高,是促凝关键载体。
- 靶向EV膜阴离子磷脂的抗凝策略可改善TBI结局。
核心结论
- 靶向表达阴离子磷脂的细胞外囊泡的抗凝治疗可预防TBI诱导的凝血病并改善小鼠结局。
研究设计与样本
- 研究结合小鼠重型TBI模型与体外实验,评估融合蛋白ANV-6L15的治疗效果。
- 小鼠模型采用1.9 atm液压冲击伤。
主要发现
- ANV-6L15使颅内血肿减少70.2%,改善神经功能,使死亡减少56.8%。
- ANV-6L15可防止血管渗漏、组织水肿及TBI诱导的高凝状态。
- 外源性tenase复合物在循环EV表面形成,BDEVs上水平最高。
- 磷脂组学分析显示BDEVs的磷脂酰丝氨酸水平为79.1 nM/mg蛋白,内皮细胞EV为15.2 nM/mg,血小板EV为3.5 nM/mg。
临床怎么用
- 提示靶向EV膜阴离子磷脂的抗凝策略可能用于TBI相关凝血病的防治。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe traumatic brain injury (TBI) often causes an acute systemic hypercoagulable state that rapidly develops into consumptive coagulopathy. We have recently demonstrated that TBI-induced coagulopathy (TBI-IC) is initiated and disseminated by brain-derived extracellular vesicles (BDEVs) and propagated by extracellular vesicles (EVs) from endothelial cells and platelets. Here, we present results from a study designed to test the hypothesis that anticoagulation targeting anionic phospholipid-expressing EVs prevents TBI-IC and improves the outcomes of mice subjected to severe TBI. We evaluated the effects of a fusion protein (ANV-6L15) for improving the outcomes of TBI in mouse models combined with in vitro experiments. ANV-6L15 combines the phosphatidylserine (PS)-binding annexin V (ANV) with a peptide anticoagulant modified to preferentially target extrinsic coagulation. We found that ANV-6L15 reduced intracranial hematoma by 70.2%, improved neurological function, and reduced death by 56.8% in mice subjected to fluid percussion injury at 1.9 atm. It protected the TBI mice by preventing vascular leakage, tissue edema, and the TBI-induced hypercoagulable state. We further showed that the extrinsic tenase complex was formed on the surfaces of circulating EVs, with the highest level found on BDEVs. The phospholipidomic analysis detected the highest levels of PS on BDEVs, as compared with EVs from endothelial cells and platelets (79.1, 15.2, and 3.5 nM/mg of protein, respectively). These findings demonstrate that TBI-IC results from a trauma-induced hypercoagulable state and may be treated by anticoagulation targeting on the anionic phospholipid-expressing membrane of EVs from the brain and other cells.
引用
- Dong X, Liu W, Shen Y, et al. Anticoagulation targeting membrane-bound anionic phospholipids improves outcomes of traumatic brain injury in mice. Blood. 2021. PMID: 34610086. doi:10.1182/blood.2021011310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。